Insulin prices, availability and affordability: A cross-sectional survey of pharmacies in Hubei Province, China

BMC Health Services Research

Volumn 17, Issue 1, 2017, Pages

  Liu, Chenxi ^a   Zhang, Xinping ^a   Liu, Chaojie ^b   Ewen, Margaret ^c   Zhang, Zinan ^a   Liu, Guoqin ^d  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b LA TROBE UNIVERSITY   (Australia)

^c Vancouver BC   (Netherlands)

^d ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Access; Affordability; Availability; China; Diabetes; Insulin; Price component; WHO HAI

Indexed keywords

ESSENTIAL DRUG; INSULIN;

CHINA; CROSS-SECTIONAL STUDY; ECONOMICS; FEE; HEALTH CARE DELIVERY; HUMAN; PHARMACY; PUBLIC HOSPITAL; PUBLIC SECTOR; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

CHINA; CROSS-SECTIONAL STUDIES; DRUGS, ESSENTIAL; HEALTH SERVICES ACCESSIBILITY; HOSPITALS, PUBLIC; HUMANS; INSULIN; PHARMACIES; PRESCRIPTION FEES; PUBLIC SECTOR;

EID: 85028318032     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-017-2553-0     Document Type: Article

References (41)

1. WHO. Global status report on noncommunicable diseases. Geneva: World Health Organization; 2014.
2. WHO. Global Action Plan for the Prevention and Control of Noncommunicable diseases 2013-2020. Geneva: World Health Organization; 2013.
3. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet. 2010;375(9712):408-18.
4. Seshasai SR, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-41.
5. UN. Prevention and control of non-communicable diseases: report of the secretary-general. New York: United Nations; 2011.
6. Madeb R, Koniaris LG, Schwartz SI. The discovery of insulin: the Rochester, New York, connection. Ann Intern Med. 2005;143(12):907-12.
7. Bliss M. The discovery of insulin. Chicago: University of Chicago Press; 1984.
8. Miller RG, et al. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh epidemiology of diabetes complications study cohort. Diabetes. 2012;61(11):2987-92.
9. WHO. Global report on diabetes. Geneva: World Health Organization; 2016.
10. Beran D, Yudkin JS. Diabetes care in sub-Saharan Africa. Lancet. 2006;368(9548):1689-95.
11. Holmes D. Linong Ji: fighting to turn the tide against diabetes in China. Lancet. 2014;383(9933):1961.
12. Hoyer CB, Christensen EF, Eika B. Standards of resuscitation during inter-hospital transportation: the effects of structured team briefing or guideline review - a randomised, controlled simulation study of two micro-interventions. Scand J Trauma, Resusc Emerg Med. 2011;19:15.
13. Currie CJ, Peters JR, Evans M. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008. Diabet Med. 2010;27(7):744-52.
14. Wild S, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.
15. Xu Y, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948-59.
16. Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.
17. Zhao Z, et al. Rapidly rising incidence of childhood type 1 diabetes in Chinese population: epidemiology in shanghai during 1997-2011. Acta Diabetol. 2014;51(6):947-53.
18. Yang Z, et al. Childhood diabetes in China: enormous variation by place and ethnic group. Diabetes Care. 1998;21(4):525.
19. GBD, The Global Health Data Exchange. Diabetes Mellitus in Hubei [Aggregated online database]. 2016, Global Burden of Disease Study, the Institute for Health Metrics and Evaluation (IHME) at the University of Washington: The Global Health Data Exchange (ghdx.healthdata.org). http://global-disease-burden.healthgrove.com/l/66349/Diabetes-Mellitus-in-Hubei. Accessed 19 Aug 2017.
20. SCIOPRC. Progress in China's Human Rights in 2014. 2015, the state council information Office of the People's Republic of China: Beijing, China.
21. WB. Out-of-pocket health expenditure (% of private expenditure on health). 2014, The World Bank. http://data.worldbank.org/indicator/SH.XPD.OOPC.ZS?locations=CN. Accessed 19 Aug 2017.
22. MoH. Further standardize centralized tender and procurement of drugs in medical institutions. 2004, Ministry of Health: Beijing, China.
23. NDRC. Standardize the price management of medical services and related issues. 2012, National Development and Reform Commission: Beijing, China.
24. NDRC. Promote the reform of medicine prices. 2015.6, National Development and Reform Commission: Beijing, China.
25. WHO/HAI. Measuring medicine prices, availability, affordability and price components. Switzerland: World Health Organization and Health Action International; 2008.
26. World Health Organization. Price, availability and affordability: an international comparison of chronic disease medicines. 2006. http://apps.who.int/iris/bitstream/10665/116493/1/dsa560.pdf.
27. DoH. Standard Packs and Prices for Ready Prepared Pharmaceutical Benefits. 2016, Department of Health, Australia Government. http://www.pbs.gov.au/browse/medicine-listing.
28. Babar ZU, et al. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007;4(3):e82.
29. Gelders S, et al. Price, availability and affordability: an international comparison of chronic disease medicines. 2006.
30. Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol. 2016;4(3):275-85.
31. Jiang M, Yang S, Yan K, et al. Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi province of China. PLoS One. 2013;8(8):e70836.
32. HAI. Database of medicine prices, availability, affordability and price components [Online database]. 2012, Health Action International. http://haiweb.org/what-we-do/price-availability-affordability/price-availability-data/. Accessed 19 Aug 2017.
33. Cefalu WT. American diabetes association, standards of medicial care in diabetes-2016. Diabetes Care. 2016;39(supplement 1):6.
34. GOPG. Notice on adjusting the minimum wage standards of Hubei Province. Wuhan: General Office of the Provincial Government, the People 's Government of Hubei Province; 2015.
35. Wang Y. Medical Service and Health Insurance of the Middle and Low - income Groups in China. 2010: China Financial and Economic Press. p. 562.
36. Luo J, Kesselheim AS. Evolution of insulin patents and market exclusivities in the USA. Lancet Diabetes Endocrinol. 2015;3(11):835-7.
37. Chen C, Dong W, Shen JJ, et al. Is the prescribing behavior of Chinese physicians driven by financial incentives? Soc Sci & Med. 2014;120:40-48.
38. Ewen M, et al. Insulin prices profile. 2016, Health Action International. p. 6. http://haiweb.org/wp-content/uploads/2016/04/ACCISS-Prices-report-FINAL-1.pdf. Accessed 19 Aug 2017.
39. CFDA. Online database of registered medicines. Beijing: China Food and Drug Administration; 2016.
40. Al-Sharayri MGA, Aljbori TM, Abu-Rumman TM. A. E. K. Insulin vials vs. insulin cartridges: Further cost considerations. Saudi Pharm J. 2013;21(2):225-7.
41. GOSC. Guiding opinions on promoting the construction of hierarchical medical system. Beijing: General Office of the State Council; 2015.